Research programme: Alzheimer's disease therapies - Orion Acquisition Corp. IIAlternative Names: NT 0904
Latest Information Update: 02 Sep 2009
At a glance
- Originator Orion Acquisition Corp II
- Class Small molecules
- Mechanism of Action AMPA receptor antagonists; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 05 Sep 2005 Preclinical trials in Alzheimer's disease in USA (PO)